• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
RDEA119

RDEA119

Product ID R1217
Cas No. 923032-37-5
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $236.90 In stock
10 mg $382.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

RDEA119 inhibits MEK1/2 and exhibits anticancer chemotherapeutic activity. RDEA119 is currently in clinical trials as a potential treatment for a variety of advanced cancers. This compound inhibits proliferation in thyroid cancer cells, including those containing V600E B-Raf mutations. RDEA119 also inhibits tumor growth in animal models of melanoma, colon cancer, and epidermal carcinoma.

Product Info

Cas No.

923032-37-5

Purity

≥98%

Formula

C19H20F3lN2O5S

Formula Wt.

572.34

Chemical Name

Refametinib

IUPAC Name

N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

Synonym

Refametinib, BAY 869766; N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-cyclopropanesulfonamide; BAY 869766; BAY 8697661

Solubility

DMSO 100 mg/mL (174.72 mM) Ethanol 100 mg/mL (174.72 mM) Water Insoluble

Appearance

White Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

R1217 MSDS PDF

Info Sheet

R1217 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733.

Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.

Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • V9202

    VX-702

    p38 MAPK inhibitor.

    ≥98%
  • C0027

    Cafestol Linoleate

    Diterpene found in brewed, unfiltered coffee; F...

    ≥98%
  • N0163

    2-(1,8-Naphthyridin-2-yl)phenol

    Naphthalene; indirect STAT1 agonist.

    ≥98%
  • M5753

    Monensin Sodium

    Polyether ionophore, autophagy inhibitor.

    ≥98%
  • E9201

    EX-527

    SIRT1 inhibitor.

    ≥99%
  • L960006

    LY-2606368

    CHK1 inhibitor.

    ≥98%
  • M0009

    Macitentan

    ET-A/B antagonist.

    ≥99%
  • C0169

    Carbenoxolone Disodium

    Synthetic derivative of glycyrrhizin; connexin ...

    ≥97%
  • T1777

    S,S-(+)-Tetrandrine

    Benzylisoquinoline alkaloid originally found in...

    ≥98%
  • C1630

    Cefoperazone Sodium

    β-lactam cephalosporin; penicillin binding pro...

    ≥98%
  • S0072

    5S rRNA modificator

    Electrophile used in 2’-hydroxyl acylation of...

    ≥98%
  • C6132

    CPI-203

    Triazolothienodiazepine, JQ-1 derivative; BRD i...

    ≥98%
  • C0246

    Calcimycin

    Polyether pyrrole, divalent cation ionophore.

    ≥98%
  • Z5745

    Zolmitriptan

    5-HT1B/1D agonist.

    ≥99%
  • V0252

    Vancomycin Hydrochloride

    Glycopeptide, binds D-Ala-D-Ala; cell wall synt...

    ≥1050 IU/mg, bio assay
  • T1002

    2-Debenzoyl Paclitaxel-2-(2-Methyl-2-Butenoate)

    Synthesis intermediate

    ≥95%
  • N4524

    NLG919

    Indoleamine-2,3-dioxygenase inhibitor.

    ≥98%
  • T6803

    Trandolapril

    ACE inhibitor.

    ≥98%
  • C1637

    Ceftriaxone Disodium Hemiheptahydrate

    β-lactam cephalosporin; penicillin binding pro...

    ≥98%
  • M1680

    5-Methoxyindole

    Core structure of melatonin; potential PPARγ a...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only